Active, not recruitingPhase 2NCT04784247

Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma

Studying Soft tissue sarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Sujana Movva, MD
Memorial Sloan Kettering Cancer Center
Intervention
Lenvatinib(drug)
Enrollment
52 target
Eligibility
18 years · All sexes
Timeline
20212026

Study locations (7)

Collaborators

Merck Sharp & Dohme LLC · Parker Institute for Cancer Immunotherapy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04784247 on ClinicalTrials.gov

Other trials for Soft tissue sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Soft tissue sarcoma

← Back to all trials